Physician profile
John A Morytko
NPI 1356385736
$4,881.75
in general payments reported to CMS, 2019-2025
34 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $484 · 2021: $386 · 2022: $579 · 2023: $782 · 2024: $516 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.61 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,046.24 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $488.45 | 2022-2025 | Symplicity G3, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $445.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $442.58 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $366.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $284.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $243.02 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $214.28 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $208.99 | 2020-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $202.77 | 2019-2025 | Watchman Flx, General - Therapies |
| Stryker Corporation | $119.37 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.25 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $83.67 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $74.69 | 2019 | |
| Abbott Laboratories | $67.82 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $61.26 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $60.10 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $40.59 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $35.96 | 2019-2021 | |
| Lilly USA, LLC | $33.39 | 2025 | Mounjaro, Zepbound |
| Akcea Therapeutics, INC. | $33.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.19 | 2025 | |
| Esperion Therapeutics, INC. | $24.90 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2025 | Keveyis |
| Kestra Medical Technology Services, INC. | $21.83 | 2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $21.33 | 2024 | Optimizer |
| Heartflow, INC. | $19.70 | 2024 | |
| Currax Pharmaceuticals LLC | $17.59 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.43 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $15.51 | 2024 | |
| Allergan, INC. | $13.44 | 2019 | |
| Cvrx, INC. | $12.43 | 2023 | Barostim Neo System |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morytko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.